These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18645937)

  • 1. Safety and toxicity of a new formulated Leishmania major preliminary vaccine in animal model Balb/c and small white conventional laboratory mice.
    Latifynia A; Hazrati SM
    Turkiye Parazitol Derg; 2008; 32(2):103-8. PubMed ID: 18645937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effects of a new formulation of Leishmania major antigen in Balb/C and conventional white laboratory mice.
    Latifynia A; Hazrati SM
    J Microbiol Immunol Infect; 2010 Apr; 43(2):138-46. PubMed ID: 20457431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
    Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
    Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
    Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
    Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post challenging serum cytokine profile (Th1 & Th2) in the vaccinated mice (Balb/C) with a new formulation of Leishmania major antigen.
    Latifynia A; Khamisipour A; Gharagozlou MJ; Bokaie S; Vodjgani M; Gheflati Z; Mosavi M; Khansari N
    Turkiye Parazitol Derg; 2013; 37(4):233-40. PubMed ID: 24412861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
    Eskandari F; Talesh GA; Parooie M; Jaafari MR; Khamesipour A; Saberi Z; Abbasi A; Badiee A
    Exp Parasitol; 2014 Nov; 146():78-86. PubMed ID: 25246326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania major: species specific delayed hypersensitivity reaction induced by exogenous secreted antigen in the guinea pig.
    Khabiri AR; Bagheri F; Assmar M
    Exp Parasitol; 2006 Mar; 112(3):184-6. PubMed ID: 16376333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-).
    Xu D; McSorley SJ; Chatfield SN; Dougan G; Liew FY
    Immunology; 1995 May; 85(1):1-7. PubMed ID: 7635511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major.
    Ghaffarifar F; Jorjani O; Sharifi Z; Dalimi A; Hassan ZM; Tabatabaie F; Khoshzaban F; Hezarjaribi HZ
    APMIS; 2013 Apr; 121(4):290-8. PubMed ID: 23030526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.
    Gicheru MM; Olobo JO; Anjili CO; Orago AS; Modabber F; Scott P
    Infect Immun; 2001 Jan; 69(1):245-51. PubMed ID: 11119512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania major: common antigen responsible for induction of delayed-type hypersensitivity response in guinea pigs.
    Khabiri AR; Bagheri F; Assmar M
    Parasitol Res; 2007 Feb; 100(3):629-32. PubMed ID: 17013648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice.
    Soudi S; Hosseini AZ; Hashemi SM
    Parasite Immunol; 2011 Oct; 33(10):561-71. PubMed ID: 21781137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.